• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用与体外消化-渗透模型比较的方法,构建了具有生理相关的膜表面积/体积比的体外消化-原位吸收装置,用于评价脂质体制剂的性能。

In Vitro Digestion-In Situ Absorption Setup Employing a Physiologically Relevant Value of the Membrane Surface Area/Volume Ratio for Evaluating Performance of Lipid-Based Formulations: A Comparative Study with an In Vitro Digestion-Permeation Model.

机构信息

Laboratory of Drug Delivery System, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan.

Laboratory of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hiro-koshingai, Kure, Hiroshima 737-0112, Japan.

出版信息

Mol Pharm. 2024 Jul 1;21(7):3459-3470. doi: 10.1021/acs.molpharmaceut.4c00161. Epub 2024 May 29.

DOI:10.1021/acs.molpharmaceut.4c00161
PMID:38809159
Abstract

The aim of this study is to establish and test an in vitro digestion-in situ absorption model that can mimic in vivo drug flux by employing a physiologically relevant value of the membrane surface area ()/volume () ratio for accurate prediction of oral drug absorption from lipid-based formulations (LBFs). Three different types of LBFs (Type IIIA-MC, Type IIIA-LC, and Type IV) loaded with cinnarizine (CNZ), a lipophilic weak base with borderline permeability, and a control suspension were prepared. Subsequently, a simultaneous in vitro digestion-permeation experiment was conducted using a side-by-side diffusion cell with a dialysis membrane having a low / value. During digestion, CNZ partially precipitated for Type IV, while it remained solubilized in the aqueous phase for Type IIIA-MC and Type IIIA-LC in the donor compartment. However, in vitro drug fluxes for Type IIIA-MC and Type IIIA-LC were lower than those for Type IV due to the reduced free fraction of CNZ in the donor compartment. In pharmacokinetic studies, a similar improvement in in vivo oral exposure relative to suspension was observed, regardless of the LBFs used. Consequently, a poor correlation was found between in vitro permeation and areas under the plasma concentration-time curve (AUC) ( = 0.087). A luminal concentration measurement study revealed that this discrepancy was attributed to the extremely high absorption rate of CNZ in the gastrointestinal tract compared to that across a dialysis membrane evaluated by the in vitro digestion-permeation model, i.e., the absorption of CNZ in vivo was completed regardless of the extent of the free fraction, owing to the rapid removal of CNZ from the intestine. Subsequently, we aimed to predict the oral absorption of CNZ from the same formulations using a model that demonstrated high drug flux by employing the physiologically relevant / value and rat jejunum segment as an absorption sink (for replicating in vivo intestinal permeability). Predigested formulations were injected into the rat intestinal loop, and AUC values were calculated from the plasma concentration-time profiles. A better correlation was found between AUC and AUC ( = 0.72), although AUC underestimated AUC for Type IV due to the precipitation of CNZ during the predigestion process. However, this result indicated the importance of mimicking the in vivo drug absorption rate in the predictive model. The method presented herein is valuable for the development of LBFs.

摘要

本研究旨在建立并验证一种体外消化-原位吸收模型,该模型采用与生理相关的膜表面积()/体积()比值,以模拟体内药物通量,从而准确预测脂质体制剂(LBFs)的口服药物吸收。本研究制备了三种不同类型的 LBFs(Type IIIA-MC、Type IIIA-LC 和 Type IV),载有辛尼嗪(CNZ),一种具有边缘渗透性的亲脂性弱碱,并制备了对照混悬剂。随后,采用具有低 / 值的侧-侧扩散池进行体外同步消化-渗透实验。在消化过程中,Type IV 中的 CNZ 部分沉淀,而在供体室中,Type IIIA-MC 和 Type IIIA-LC 中的 CNZ 仍保持溶解于水相。然而,由于供体室中 CNZ 的游离分数降低,Type IIIA-MC 和 Type IIIA-LC 的药物通量低于 Type IV。在药代动力学研究中,无论使用何种 LBF,与混悬剂相比,均观察到体内口服暴露的改善。因此,体外渗透与血浆浓度-时间曲线下面积(AUC)之间的相关性较差(=0.087)。腔内浓度测量研究表明,这种差异归因于与体外消化-渗透模型评估的透析膜相比,CNZ 在胃肠道中的极高吸收速率,即 CNZ 在体内的吸收无论游离分数的程度如何,都完成了,因为 CNZ 从肠道中迅速被清除。随后,我们旨在使用一种在预测模型中显示高药物通量的模型,预测相同制剂中 CNZ 的口服吸收,该模型采用与生理相关的 / 值和大鼠空肠段作为吸收池(复制体内肠通透性)。对预消化制剂进行注射,并从血浆浓度-时间曲线计算 AUC 值。AUC 与 AUC 之间的相关性更好(=0.72),尽管由于 CNZ 在预消化过程中的沉淀,Type IV 的 AUC 低估了 AUC。然而,这一结果表明在预测模型中模拟体内药物吸收速率的重要性。本文提出的方法对于 LBFs 的开发具有重要价值。

相似文献

1
In Vitro Digestion-In Situ Absorption Setup Employing a Physiologically Relevant Value of the Membrane Surface Area/Volume Ratio for Evaluating Performance of Lipid-Based Formulations: A Comparative Study with an In Vitro Digestion-Permeation Model.采用与体外消化-渗透模型比较的方法,构建了具有生理相关的膜表面积/体积比的体外消化-原位吸收装置,用于评价脂质体制剂的性能。
Mol Pharm. 2024 Jul 1;21(7):3459-3470. doi: 10.1021/acs.molpharmaceut.4c00161. Epub 2024 May 29.
2
Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.不同脂质给药系统中,脂质消化和药物渗透/再溶解对口服利托那韦吸收的影响。
Eur J Pharm Sci. 2021 Feb 1;157:105604. doi: 10.1016/j.ejps.2020.105604. Epub 2020 Oct 22.
3
Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro.用于体外同时研究消化和吸收的脂肪分解渗透装置。
Mol Pharm. 2019 Mar 4;16(3):921-930. doi: 10.1021/acs.molpharmaceut.8b00811. Epub 2019 Jan 29.
4
Absorption of cinnarizine from type II lipid-based formulations: Impact of lipid chain length, supersaturation, digestion, and precipitation inhibition.辛尼嗪从 II 型脂质体制剂中的吸收:脂质链长、过饱和度、消化和沉淀抑制的影响。
Eur J Pharm Sci. 2024 Jun 1;197:106765. doi: 10.1016/j.ejps.2024.106765. Epub 2024 Apr 10.
5
Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability.基于脂质的配方的消化不仅由于溶解度的差异而影响到脂溶性差的药物的吸收变化,而且还反映了热力学活性和通透性的变化。
Mol Pharm. 2021 Apr 5;18(4):1768-1778. doi: 10.1021/acs.molpharmaceut.1c00015. Epub 2021 Mar 17.
6
Assessment of in Vivo Performance of Lipid-Based Formulations: Correlation between in Vitro Drug Release Profiles and in Vivo Absorption Rate Profiles.脂质体制剂体内性能评价:体外药物释放谱与体内吸收速率谱的相关性。
Biol Pharm Bull. 2024;47(10):1616-1623. doi: 10.1248/bpb.b24-00458.
7
In vivo evaluation of supersaturation/precipitation/re-dissolution behavior of cinnarizine, a lipophilic weak base, in the gastrointestinal tract: the key process of oral absorption.脂溶性弱碱桂利嗪在胃肠道中的过饱和/沉淀/再溶解行为的体内评价:口服吸收的关键过程
Eur J Pharm Sci. 2017 Jan 1;96:464-471. doi: 10.1016/j.ejps.2016.10.023. Epub 2016 Oct 20.
8
Suitability of Artificial Membranes in Lipolysis-Permeation Assays of Oral Lipid-Based Formulations.人工膜在口服脂质体制剂透皮吸收研究中的适用性。
Pharm Res. 2020 May 20;37(6):99. doi: 10.1007/s11095-020-02833-9.
9
Digestion is a critical element for absorption of cinnarizine from supersaturated lipid-based type I formulations.消化是从超饱和脂质型 I 制剂中吸收肉桂嗪的关键因素。
Eur J Pharm Sci. 2024 Jan 1;192:106634. doi: 10.1016/j.ejps.2023.106634. Epub 2023 Nov 10.
10
In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.采用分散和消化试验对无药物和非诺贝特载脂体制剂进行体外评估,可深入了解制剂在肠道中的可能命运。
Eur J Pharm Sci. 2013 Jul 16;49(4):748-60. doi: 10.1016/j.ejps.2013.04.036. Epub 2013 May 16.

引用本文的文献

1
Application of a Novel Dissolution Medium with Lipids for In Vitro Simulation of the Postprandial Gastric Content.一种含脂质的新型溶出介质在体外模拟餐后胃内容物中的应用。
Pharmaceutics. 2024 Aug 3;16(8):1040. doi: 10.3390/pharmaceutics16081040.